RecruitingPhase 3NCT06597019
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Studying Rare hypercholesterolemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Inclisiran(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 6-11 years · All sexes
- Timeline
- 2024 – 2029
Study locations (30)
- UC San Francisco Medical Center, San Francisco, California, United States
- Children's National Hospital, Washington D.C., District of Columbia, United States
- Childrens National Hospital, Washington D.C., District of Columbia, United States
- Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
- Icahn School of Med at Mt Sinai, New York, New York, United States
- Primary Childrens Medical Center, Salt Lake City, Utah, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
- West Virginia Childrens Hospital, Morgantown, West Virginia, United States
- Novartis Investigative Site, Buenos Aires, Argentina
- Novartis Investigative Site, CABA, Argentina
- Novartis Investigative Site, Salzburg, Austria
- Novartis Investigative Site, Vienna, Austria
- Novartis Investigative Site, Brussels, Belgium
- Novartis Investigative Site, Leuven, Belgium
- Novartis Investigative Site, Fortaleza, Ceará, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06597019 on ClinicalTrials.govOther trials for Rare hypercholesterolemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07470723The ORIGIN-FH StudyUniversity of Wisconsin, Madison
- RECRUITINGNANCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)Nantes University Hospital
- RECRUITINGPHASE2, PHASE3NCT07058077A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)Merck Sharp & Dohme LLC
- RECRUITINGNCT06958315Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE StudyNovartis Pharmaceuticals
- RECRUITINGNCT04529967Child-Parent Familial Hypercholesterolemia ScreeningChildren's Hospital of Fudan University
- RECRUITINGPHASE3NCT06597006Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaNovartis Pharmaceuticals
- RECRUITINGNCT06634160Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial HypercholesterolemiaNantes University Hospital
- ACTIVE NOT RECRUITINGNANCT06331195An Adapted Brazilian Cardioprotective Diet, Phytosterols and Krill Oil in Familial Hypercholesterolemia (DICA-FH)Hospital do Coracao